Navin Fluorine International Limited (NFIL) has commenced commercial production at Phase 1 of its new cGMP-4 facility in Dewas, marking the full operationalization of its ₹160 crore investment. The company announced on December 31, 2025, that commercial production began following successful validation of batches by its European partner.

Facility Investment and Specifications

The cGMP-4 facility represents a significant milestone in the company's expansion strategy. The completed Phase 1 facility details are outlined below:

Validation and Production Timeline

The facility has successfully completed its validation phase with a European partner, a critical step that preceded the commencement of commercial operations. This validation process ensures that the facility meets international quality standards and regulatory requirements essential for serving global pharmaceutical markets.

Strategic Development Phases

Navin Fluorine International has adopted a phased approach for the cGMP-4 facility development:

Regulatory Compliance and Market Position

The cGMP-4 designation indicates adherence to strict regulatory requirements, positioning the facility to serve global pharmaceutical markets effectively. The successful validation by a European partner demonstrates the facility's capability to meet international quality standards from the outset of operations.

Company Communication

In its regulatory filing to BSE and NSE, Navin Fluorine International stated that commercial production commenced following "successful validation of batches by our European partner." This development represents the culmination of the company's earlier announcements regarding the facility's construction completion and commissioning readiness.

The commencement of commercial production at the Dewas facility strengthens Navin Fluorine's manufacturing capabilities and enhances its position in the specialty chemicals and pharmaceutical intermediates sectors.

Navin Fluorine International Limited has completed the allotment of 2,850 equity shares to eligible employees under its Employees Stock Option Scheme 2017 on December 18, 2025. The allotment was executed following the exercise of stock options by employees and was approved by the company's Nomination and Remuneration Committee.

Share Allotment Details

The allotment specifics are presented in the following table:

Updated Share Capital Structure

Following this allotment, Navin Fluorine International's share capital structure has been updated as follows:

Share Rights and Ranking

The newly allotted equity shares will rank pari-passu in all respects with the existing equity shares of the company. This means the new shares carry identical rights and privileges as the current shareholding, including voting rights, dividend entitlements, and other corporate benefits.

Corporate Communication

The company has formally notified both BSE Limited and National Stock Exchange of India Limited about this allotment. Navin Fluorine International trades on BSE under scrip code 532504 and on NSE under the symbol NAVINFLUOR. The communication was signed by Niraj B. Mankad, President Legal and Company Secretary, ensuring compliance with regulatory disclosure requirements.